BR0014192A - Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores - Google Patents

Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores

Info

Publication number
BR0014192A
BR0014192A BR0014192-5A BR0014192A BR0014192A BR 0014192 A BR0014192 A BR 0014192A BR 0014192 A BR0014192 A BR 0014192A BR 0014192 A BR0014192 A BR 0014192A
Authority
BR
Brazil
Prior art keywords
dye
target structures
representation
antibody conjugates
tumor margin
Prior art date
Application number
BR0014192-5A
Other languages
English (en)
Inventor
Michael Schirner
Kai Licha
Ludger Dinkelborg
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7924318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0014192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0014192A publication Critical patent/BR0014192A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: "CONJUGADOS DE CORANTES E ANTICORPOS CONTRA ESTRUTURAS-ALVO DA ANGIOGêNESE, PARA REPRESENTAçãO INTRA-OPERATIVA DA MARGEM DE TUMORES". A invenção descreve conjugados de anticorpos e corantes, que são apropriados para ligar-se a estruturas de vasos recém-formados e o uso dos mesmos para a representação intra-operativa da angiogênese
BR0014192-5A 1999-09-24 2000-08-19 Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores BR0014192A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19947559A DE19947559A1 (de) 1999-09-24 1999-09-24 Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
PCT/EP2000/008121 WO2001023005A1 (de) 1999-09-24 2000-08-19 Antikörper-farbstoffkonjugate gegen zielstrukturen der angiogenese zur intraoperativen tumorranddarstellung

Publications (1)

Publication Number Publication Date
BR0014192A true BR0014192A (pt) 2002-05-21

Family

ID=7924318

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014192-5A BR0014192A (pt) 1999-09-24 2000-08-19 Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores

Country Status (22)

Country Link
EP (2) EP1532988A3 (pt)
JP (1) JP2003510294A (pt)
KR (2) KR20070087232A (pt)
CN (1) CN1269530C (pt)
AU (1) AU779026B2 (pt)
BG (1) BG65682B1 (pt)
BR (1) BR0014192A (pt)
CA (1) CA2385593A1 (pt)
CZ (1) CZ2002991A3 (pt)
DE (1) DE19947559A1 (pt)
EE (1) EE05176B1 (pt)
HU (1) HUP0202625A2 (pt)
IL (2) IL148405A0 (pt)
MX (1) MXPA02002639A (pt)
NO (1) NO20021441L (pt)
NZ (1) NZ517944A (pt)
RO (1) RO121598B1 (pt)
RU (1) RU2002109237A (pt)
SK (1) SK3972002A3 (pt)
WO (1) WO2001023005A1 (pt)
YU (1) YU20702A (pt)
ZA (1) ZA200203225B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524018A (ja) 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
US6440389B1 (en) * 2000-07-19 2002-08-27 The General Hospital Corporation Fluorescent agents for real-time measurement of organ function
AT413487B (de) 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
NO20034351D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av endometrose
ATE374367T1 (de) * 2004-07-22 2007-10-15 Bayer Schering Pharma Ag Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
AU2010239272B2 (en) * 2009-04-21 2015-09-17 The University Of Utah Research Foundation Light-emitting dye for intraoperative imaging or sentinel lymph node biopsy
EP3493855A4 (en) * 2016-08-02 2020-04-01 ISI Life Sciences, Inc. COMPOSITIONS AND METHOD FOR DETECTING CANCER CELLS IN A TISSUE SAMPLE
JP7344982B2 (ja) * 2019-11-21 2023-09-14 富士フイルム株式会社 化合物及びこれを用いた蛍光標識生体物質

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341223A (en) * 1981-02-04 1982-07-27 Lutz Lauralee A Fluoresceable composition and method of determining fluid flow
AU702250B2 (en) * 1994-07-11 1999-02-18 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis

Also Published As

Publication number Publication date
HUP0202625A2 (en) 2002-12-28
AU779026B2 (en) 2005-01-06
KR20020039349A (ko) 2002-05-25
BG65682B1 (bg) 2009-06-30
MXPA02002639A (es) 2002-07-30
AU6702600A (en) 2001-04-30
RO121598B1 (ro) 2007-12-28
JP2003510294A (ja) 2003-03-18
BG106528A (bg) 2002-12-29
CN1269530C (zh) 2006-08-16
HK1050491A1 (en) 2003-06-27
CZ2002991A3 (cs) 2002-06-12
ZA200203225B (en) 2003-07-23
CN1376074A (zh) 2002-10-23
RU2002109237A (ru) 2003-11-27
IL148405A (en) 2009-06-15
NO20021441L (no) 2002-05-15
EP1214099A1 (de) 2002-06-19
YU20702A (sh) 2005-06-10
NO20021441D0 (no) 2002-03-22
EP1532988A3 (de) 2008-09-17
NZ517944A (en) 2004-06-25
EE200200152A (et) 2003-04-15
IL148405A0 (en) 2002-09-12
KR100832937B1 (ko) 2008-05-27
SK3972002A3 (en) 2002-09-10
PL354027A1 (pl) 2003-12-15
DE19947559A1 (de) 2001-04-19
EE05176B1 (et) 2009-06-15
WO2001023005A1 (de) 2001-04-05
CA2385593A1 (en) 2001-04-05
KR20070087232A (ko) 2007-08-27
EP1532988A2 (de) 2005-05-25

Similar Documents

Publication Publication Date Title
BR9909795A (pt) Derivados de epotilona 12, 13-modificados
ID29994A (id) Komposisi farmasi untuk melawan ccr5 terdiri dari turunan anilida
MA26548A1 (fr) Compositions pharmaceutiques topiques contenant des derives de resorcinol.
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
TR199800436A3 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
BR9805544C1 (pt) Uso de um composto.
EA200100111A1 (ru) Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
BR0014491A (pt) Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão
BR0109107A (pt) Usos terapêuticos de mediadores ppar
BR9915515B1 (pt) composiÇço curÁvel de multicomponentes.
BR9912327A (pt) Inibidores da uroquinase
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
BR0014378A (pt) Derivados de ácido indolil-3-glioxìlico tendo propriedades terapeuticamente valiosas
BR0015490A (pt) Combinações oncolìticas para o tratamento de câncer
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
BR0014192A (pt) Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores
MA26460A1 (fr) Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent.
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
DE59005313D1 (de) 2-Methyl- und 2-Hydroxymethyl-serin-N,N-diessigsäure und ihre Derivate.
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
ATE240100T1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
BR0017046A (pt) Uso de azóis para prevenção de câncer de pele

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 10, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.